Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XC221 in Uncomplicated Influenza and Viral URIs
NCT05030324Phase 2Completed
- Sponsor
- Valenta Pharm
- Start
- Oct 2021
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of aterixen in influenza, acute viral upper respiratory infection, sponsored by Valenta Pharm. Started Oct 2021; status: completed.
02
Drugs
aterixen
03
Conditions
influenzaacute viral upper respiratory infection
Beyond the preview
Go deeper on NCT05030324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05030324.